Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Yau T, et al. Among authors: curran d. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13. Lancet Gastroenterol Hepatol. 2024. PMID: 38364832 Clinical Trial.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: curran d. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Pal SK, et al. Among authors: curran d. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7. J Clin Oncol. 2021. PMID: 34491815 Free PMC article. Clinical Trial.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin YC, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T. Neal J, et al. Among authors: curran d. J Clin Oncol. 2024 Jul 10;42(20):2393-2403. doi: 10.1200/JCO.23.02166. Epub 2024 Mar 29. J Clin Oncol. 2024. PMID: 38552197 Free PMC article. Clinical Trial.
How prevalent are lactoferrin receptors in Gram-negative bacteria?
Ewasechko NF, Curran DM, Yu Khaw K, Schryvers AB. Ewasechko NF, et al. Among authors: curran dm. Biochem Cell Biol. 2025 Jan 9. doi: 10.1139/bcb-2024-0180. Online ahead of print. Biochem Cell Biol. 2025. PMID: 39783447 Free article. Review.
Constraints on Covariant Dark-Matter-Nucleon Effective Field Theory Interactions from the First Science Run of the LUX-ZEPLIN Experiment.
Aalbers J, Akerib DS, Al Musalhi AK, Alder F, Amarasinghe CS, Ames A, Anderson TJ, Angelides N, Araújo HM, Armstrong JE, Arthurs M, Baker A, Balashov S, Bang J, Barillier EE, Bargemann JW, Beattie K, Benson T, Bhatti A, Biekert A, Biesiadzinski TP, Birch HJ, Bishop EJ, Blockinger GM, Boxer B, Brew CAJ, Brás P, Burdin S, Buuck M, Carmona-Benitez MC, Carter M, Chawla A, Chen H, Cherwinka JJ, Chin YT, Chott NI, Converse MV, Cottle A, Cox G, Curran D, Dahl CE, David A, Delgaudio J, Dey S, de Viveiros L, Di Felice L, Ding C, Dobson JEY, Druszkiewicz E, Eriksen SR, Fan A, Fearon NM, Fiorucci S, Flaecher H, Fraser ED, Fruth TMA, Gaitskell RJ, Geffre A, Genovesi J, Ghag C, Gibbons R, Gokhale S, Green J, van der Grinten MGD, Haiston JJ, Hall CR, Han S, Hartigan-O'Connor E, Haselschwardt SJ, Hernandez MA, Hertel SA, Heuermann G, Homenides GJ, Horn M, Huang DQ, Hunt D, Jacquet E, James RS, Johnson J, Kaboth AC, Kamaha AC, Kannichankandy M, Khaitan D, Khazov A, Khurana I, Kim JD, Kim J, Kingston J, Kirk R, Kodroff D, Korley L, Korolkova EV, Kraus H, Kravitz S, Kreczko L, Kudryavtsev VA, Leonard DS, Lesko KT, Levy C, Lin J, Lindote A, Linehan R, Lippincott WH, Lopes MI, Lorenzon W, Lu C… See abstract for full author list ➔ Aalbers J, et al. Among authors: curran d. Phys Rev Lett. 2024 Nov 29;133(22):221801. doi: 10.1103/PhysRevLett.133.221801. Phys Rev Lett. 2024. PMID: 39672140
Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against Neisseria gonorrhoeae.
Fegan JE, Islam EA, Curran DM, Ng D, Au N, Currie EG, Zeppa J, Lam J, Schryvers AB, Moraes TF, Gray-Owen SD. Fegan JE, et al. Among authors: curran dm. bioRxiv [Preprint]. 2024 Sep 7:2024.09.07.611798. doi: 10.1101/2024.09.07.611798. bioRxiv. 2024. Update in: NPJ Vaccines. 2025 Jan 15;10(1):10. doi: 10.1038/s41541-024-01054-0 PMID: 39282273 Free PMC article. Updated. Preprint.
611 results